New drug shows promise for dialysis patients with overactive parathyroid glands
NCT ID NCT06434961
First seen Jan 07, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This study tested a new medicine called SHR6508 in 498 adults with kidney failure who were on dialysis and had secondary hyperparathyroidism (overactive parathyroid glands). The goal was to see if the drug could safely lower parathyroid hormone levels. Participants received either SHR6508 or a placebo, and researchers measured hormone changes and side effects like nausea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY HYPERPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.